Aminologics아미노로직스
074430 · KOSDAQ · ₩074430 · 아미노로직스
₩1,009▲ ₩9 (0.90%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩22B | ₩17B | ₩21B | ₩27B | ₩23B |
| Cost of sales | ₩12B | ₩13B | ₩13B | ₩15B | ₩14B |
| Gross profit | ₩9.9B | ₩3.4B | ₩7.8B | ₩13B | ₩9.1B |
| Operating income | ₩3.6B | −₩2.2B | ₩1.5B | ₩7B | ₩4.1B |
| Net income | ₩3.5B | −₩1.6B | ₩2.4B | −₩7.3B | ₩5.4B |
| Net income to shareholders | ₩3.5B | −₩1.6B | ₩2.4B | −₩7.3B | ₩5.4B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩84B | ₩57B | ₩58B | ₩56B | ₩65B |
| Current assets | ₩79B | ₩47B | ₩45B | ₩44B | ₩39B |
| Cash and equivalents | ₩26B | ₩19B | ₩12B | ₩13B | ₩8.9B |
| Total liabilities | ₩28B | ₩5.1B | ₩3.3B | ₩4.2B | ₩5.8B |
| Current liabilities | ₩28B | ₩4.3B | ₩2.7B | ₩3.4B | ₩5.4B |
| Borrowings | ₩15B | ₩1B | ₩1B | ₩1B | ₩1B |
| Total equity | ₩56B | ₩52B | ₩54B | ₩51B | ₩59B |
| Shareholders' equity | ₩56B | ₩52B | ₩54B | ₩51B | ₩59B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩2.5B | ₩7.5B | −₩218M | ₩5.2B | ₩936M |
| Free cash flow | ₩2.5B | ₩7.5B | −₩218M | ₩5.2B | ₩936M |
Consolidated where available. Amounts in won.
Also known as: Aminologics / 아미노로직스 / 074430 / KRX:074430
Source: KRX statistical information